China-based Gan & Lee Pharmaceuticals Co Ltd has started its first-in-human Phase 1 clinical trial of GLR2007, it was reported on Thursday.

The product is an internally-invented, cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, used as a potential therapy for advanced solid tumours.

The Phase one clinical trial is a multicentre, open-label, study aimed at establishing the safety, tolerability, and optimal dosing strategy of the product in patients with advanced solid tumours.